EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Caffeine Potentiates Apoptosis Induction at a Lower Dose of Oxaliplatin in HCT-116 and HT-29

Kanisha Kar, Sunandita Bhar, Diya Ghosh, Tanima Das, Bandana Debnath, Arpita Chandra

Journal of Current Oncological Trends · 2025

DOI: 10.4103/jcot.jcot_14_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Oncological Trends, 2025. Verfasst von Kanisha Kar und 5 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) continues to represent a major threat to cancer-related mortality, though advancements in diagnostic modalities and therapeutic strategies have been achieved. Oxaliplatin, a platinum-based chemotherapeutic agent with demonstrated efficacy against CRC, constitutes a cornerstone of standard treatment regimens. Nevertheless, its clinical utility is limited by drug resistance and significant adverse effects.

Objective

This study aims to investigate the modulatory effects of caffeine on the therapeutic efficacy of oxaliplatin as an anticancer agent in CRC in vitro . Materials and Methods: 3-[4,5-Dimethylthiazole-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay was performed to determine the cytotoxic effects of oxaliplatin and caffeine in monotherapy and combination on human CRC cell lines HCT-116 and HT-29 and healthy human peripheral blood mononuclear cells (PBMCs). Clonogenic assay was performed to evaluate the effect on cell proliferation. Flow cytometry-based Annexin V-FITC/PI dual staining was performed to detect apoptosis induction. The expression level of apoptosis-markers was examined by western blot.

Results

The MTT assay demonstrated dose-dependent cytotoxicity of oxaliplatin and caffeine, both as monotherapies and in combination, against HCT-116 and HT-29 cells, while sparing normal PBMCs. Combination therapy lowered oxaliplatin’s IC 50 values through synergistic and additive interactions respectively in HCT-116 and HT-29. Co-treatment suppressed cell proliferation and induced apoptosis to a degree comparable to that of oxaliplatin monotherapy, with a more pronounced effect in HCT-116.

Conclusion

These preliminary observations suggest that caffeine may enhance the anticancer efficacy of oxaliplatin and may potentially alleviate its adverse effects by enabling dose reduction in the CRC model in vitro .

Zitieren

APA

Kar, K., Bhar, S., Ghosh, D., Das, T., Debnath, B., & Chandra, A. (2025). Caffeine Potentiates Apoptosis Induction at a Lower Dose of Oxaliplatin in HCT-116 and HT-29. Journal of Current Oncological Trends. https://doi.org/10.4103/jcot.jcot_14_25

Vancouver

Kar K, Bhar S, Ghosh D, Das T, Debnath B, Chandra A. Caffeine Potentiates Apoptosis Induction at a Lower Dose of Oxaliplatin in HCT-116 and HT-29. Journal of Current Oncological Trends. 2025. doi:10.4103/jcot.jcot_14_25

BibTeX
@article{Kar2025,
  author = {Kar, Kanisha and Bhar, Sunandita and Ghosh, Diya and Das, Tanima and Debnath, Bandana and Chandra, Arpita},
  title = {Caffeine Potentiates Apoptosis Induction at a Lower Dose of Oxaliplatin in HCT-116 and HT-29},
  journal = {Journal of Current Oncological Trends},
  year = {2025},
  doi = {10.4103/jcot.jcot_14_25}
}
Kostenlos starten →